Brokerages predict that Galectin Therapeutics Inc. (NASDAQ:GALT) will report earnings of ($0.11) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Galectin Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.12). Galectin Therapeutics posted earnings of ($0.13) per share during the same quarter last year, which would suggest a positive year over year growth rate of 15.4%. The firm is expected to announce its next earnings results on Tuesday, March 27th.
According to Zacks, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.53) per share for the current fiscal year, with EPS estimates ranging from ($0.53) to ($0.52). For the next fiscal year, analysts expect that the business will report earnings of ($0.48) per share, with EPS estimates ranging from ($0.60) to ($0.35). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last issued its earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02.
Shares of Galectin Therapeutics (NASDAQ:GALT) traded down $0.05 during trading on Thursday, reaching $2.44. 321,249 shares of the company’s stock were exchanged, compared to its average volume of 435,412. Galectin Therapeutics has a 1 year low of $0.88 and a 1 year high of $3.68.
A number of hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. lifted its holdings in Galectin Therapeutics by 7.4% in the third quarter. Advisor Group Inc. now owns 519,850 shares of the company’s stock valued at $1,112,000 after buying an additional 35,850 shares during the period. Virtu KCG Holdings LLC lifted its holdings in Galectin Therapeutics by 24.4% in the second quarter. Virtu KCG Holdings LLC now owns 107,203 shares of the company’s stock valued at $264,000 after buying an additional 21,008 shares during the period. Vanguard Group Inc. lifted its holdings in Galectin Therapeutics by 18.2% in the second quarter. Vanguard Group Inc. now owns 871,510 shares of the company’s stock valued at $2,144,000 after buying an additional 134,165 shares during the period. Finally, Northern Trust Corp lifted its holdings in Galectin Therapeutics by 4.4% in the second quarter. Northern Trust Corp now owns 75,097 shares of the company’s stock valued at $185,000 after buying an additional 3,176 shares during the period. Institutional investors and hedge funds own 11.07% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3094485/brokerages-expect-galectin-therapeutics-inc-galt-to-post-0-11-earnings-per-share.html.
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.